Login
Companies $IRON
$76.59 +$0.00 (0.0%) After hours
Disc Medicine, Inc. logo

Disc Medicine, Inc.

discmedicine.com

What Do They Do?

Develops medicines for people with serious blood diseases, including treatments aimed at changing heme production and iron levels to address porphyrias, anemia, polycythemia vera and sickle cell disease.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +4% (Loss)
vs −$62.3M in Q3 FY2025
  • Sep 9, 2026 Disc reported initial Phase 2 results for DISC-3405 in polycythemia vera In one trial group, participants had fewer phlebotomy events and controlled hematocrit through week 26.
  • Feb 27, 2026 Disc approved a workforce restructuring after the FDA response letter The plan reduces the workforce by approximately 20%, primarily in commercial and supporting functions.

Treatment targets The older report named chronic kidney disease anemia and Diamond-Blackfan anemia among its targets; the latest report names inflammatory bowel disease anemia and sickle cell disease among its current targets.

Who Do They Compete With?

Competes with Agios Pharmaceuticals, Akebia Therapeutics, Amgen, Astellas Pharma, Bristol-Myers Squibb, FibroGen, GlaxoSmithKline, Incyte, Ono Pharmaceuticals, Keros Therapeutics, Merck &, Otsuka Pharmaceutical, Vifor Pharma, Clinuvel, Mitsubishi Tanabe Pharma, BridgeBio Pharma, Boehringer Ingelheim, Pfizer, Eli Lilly and, and Organon &

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support